论文部分内容阅读
目的探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)在血管瘤组织和血清中的表达水平及其临床意义。方法应用免疫组织化学法和流式细胞术检测增生期、消退期血管瘤组织中TRAIL蛋白的表达,应用酶联免疫吸附试验检测血清可溶性TRAIL(sTRAIL)的含量,分别以20例正常皮肤组织和20例健康人血清作为对照。结果组织中TRAIL蛋白相对含量在增生期、消退期血管瘤及对照组分别为1.25±0.40、1.75±0.58和1.00±0.23,各组之间比较差异有统计学意义(P<0.05)。血清中sTRAIL的含量在三组分别为(1490.06±356.56)、(1658.80±371.42)和(956.86±268.62)ng/L,在血管瘤各期较对照组均明显升高,差异有统计学意义(P<0.05),但在血管瘤两期之间差异无统计学意义(P>0.05)。结论血管瘤组织中TRAIL与血清中sTRAIL的表达不完全一致。血管瘤不同时期组织中TRAIL蛋白的表达差异有助于血管瘤的分期诊断。
Objective To investigate the expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in hemangiomas and serum and its clinical significance. Methods Immunohistochemistry and flow cytometry were used to detect the expression of TRAIL protein in the proliferative and remission hemangiomas. Serum soluble TRAIL (sTRAIL) levels were detected by enzyme-linked immunosorbent assay (ELISA). Twenty normal skin tissues and 20 normal skin tissues 20 healthy human serum as a control. Results The relative content of TRAIL protein in the proliferative phase and regression group were 1.25 ± 0.40,1.75 ± 0.58 and 1.00 ± 0.23, respectively. There was significant difference between the groups (P <0.05). The levels of sTRAIL in serum were significantly higher in the three groups (1490.06 ± 356.56), (1658.80 ± 371.42) and (956.86 ± 268.62) ng / L than those in the control group, respectively P <0.05), but there was no significant difference between the two stages of hemangiomas (P> 0.05). Conclusion The expression of TRAIL in hemangiomas is not consistent with the expression of sTRAIL in serum. The expression of TRAIL protein in different stages of hemangiomas contributes to the staging diagnosis of hemangiomas.